key: cord-0875600-7jmwokhi
authors: Li, Qiubai; Cao, Yulin; Chen, Lei; Wu, Di; Yu, Jianming; Wang, Hongxiang; He, Wenjuan; Chen, Li; Dong, Fang; Chen, Weiqun; Chen, Wenlan; Li, Lei; Ran, Qijie; Liu, Qiaomei; Ren, Wenxiang; Gao, Fei; Chen, Zhichao; Gale, Robert Peter; Hu, Yu
title: Hematological features of persons with COVID-19
date: 2020-06-11
journal: Leukemia
DOI: 10.1038/s41375-020-0910-1
sha: b33895c13ad5cec30c491cf767838ca25ecd59eb
doc_id: 875600
cord_uid: 7jmwokhi

We studied admission and dynamic demographic, hematological and biochemical co-variates in 1449 hospitalized subjects with coronavirus infectious disease-2019 (COVID-19) in five hospitals in Wuhan, Hubei province, China. We identified two admission co-variates: age (Odds Ratio [OR] = 1.18, 95% Confidence Interval [CI] [1.02, 1.36]; P = 0.026) and baseline D-dimer (OR = 3.18 [1.48, 6.82]; P = 0.003) correlated with an increased risk of death in persons with COVID-19. We also found dynamic changes in four co-variates, Δ fibrinogen (OR = 6.45 [1.31, 31.69]; P = 0.022), Δ platelets (OR = 0.95 [0.90–0.99]; P = 0.029), Δ C-reactive protein (CRP) (OR = 1.09 [1.01, 1.18]; P = 0.037), and Δ lactate dehydrogenase (LDH) (OR = 1.03 [1.01, 1.06]; P = 0.007) correlated with an increased risk of death. The potential risk factors of old age, high baseline D-dimer, and dynamic co-variates of fibrinogen, platelets, CRP, and LDH could help clinicians to identify and treat subjects with poor prognosis.

Most people with coronavirus infectious disease-2019 (COVID-19) have mild to moderate symptoms and recover after the appropriate medical intervention(s). However, 15-32 percent develop severe or critical COVID-19 with a case-fatality rate of 1-15% [1] [2] [3] [4] [5] [6] . There are few data of hematological abnormalities in persons with COVID-19 [7] [8] [9] [10] [11] [12] [13] . We studied hematological co-variates in 1449 hospitalized persons with COVID-19 in five hospitals in Wuhan, China, interrogating correlations of admission parameters with COVID-19 outcomes.

We studied subjects in seven centers of five hospitals of Union Hospital (Central Hospital, Union West Hospital, and Union Tumor Hospital), Wuhan Central Hospital, General Hospital of Central Theater Command, PLA, Wuhan Third Hospital, and Wuhan Jin-Yin-Tan Hospital between January 20, and April 4, 2020. Subjects were studied on admission for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infection by quantitative realtime reverse transcriptase-polymerase chain reaction (qRT-PCR) of nasal and pharyngeal swabs and/or blood test for anti-SARS-CoV-2 IgG/IgM antibodies using a colloidalgold-based 2019-nCoV IgG/IgM Detection Kit (Nanjing Vazyme Medical Technology, Nanjing, China). COVID-19 was diagnosed according to World Health Organization interim guidance and the Novel Coronavirus Pneumonia Diagnosis and Treatment Program of the National Health Commission of China [14, 15] . Severity of COVID-19 was graded as follows: (1) mild; mild clinical symptoms, no pneumonia on lung CT; (2) common: fever, cough and lung CT with pneumonia; (3) severe: respiratory distress (respiratory rate > 30 min −1 , oxygen saturation (O 2Sat ) ≤ 93 percent at rest and/or ratio of arterial oxygen partial pressure to fractional inspired oxygen ≤300 mmHg (P aO2 /F IO2 ); and (4) critical: aforementioned criteria of respiratory failure receiving mechanical ventilation, shock, and/or organ failure other than lung and/or intensive care unit (ICU) hospitalization [12, 15] . Subjects were treated as described below or according to Chinese government guidelines [15] [16] [17] [18] . The study was approved by the Ethics Committees of Union Hospital (2020-0095) and of Wuhan Central Hospital (2020-007). Written and oral informed consent from subjects was waived by the Ethics Committees.

Electronic medical records of subjects including epidemiological, demographic, and laboratory data. Outcomes included: (1) death; (2) alive with two successive negative SARS-Cov-2 qRT-PCR tests; (3) interval from symptoms to hospital admission, discharge, or death; (4) negative qRT-PCT test; and (5) interval from admission to COVID-19 progression. Data collection forms were reviewed and verified independently by two researchers. A third researcher adjudicated discordances.

Categorical variables were described as frequency rates and percentages and continuous variables by median and interquartile range (IQR). Significance was tested by Kruskal-Wallis test or the Fisher exact test. A two-sided P < 0.05 was considered significant. Locally weighted regression and smoothing scatterplot was performed to equate a smooth curve about the relationship between time and values of laboratory parameters. Uni-and multivariable logistic regression models were used to interrogate co-variates associated with in-hospital death. Analyses were not been adjusted for multiple comparisons. Data were analyzed as of April 4, 2020.

Baseline co-variates corelated with death from COVID-19

We analyzed data from 3559 consecutive subjects. One thousand seven hundred were excluded because of missing data of SARS-CoV-2 qRT-PCR or anti-SARS-CoV-2 IgG/ IgM, 410 with co-morbidities and/or receiving drugs that would potentially affect bone marrow function (Supplementary Fig. 1 ). The resulting study cohort was 1449 subjects.

Seven hundred and thirty-three subjects (51%) were male. Median age was 57 years (IQR, 42-66 years), 576 (40%) were 60-79 years and 66 (5%), ≥80 years. Common signs and symptoms on admission included dry (485; 43%) or productive cough (551; 38%), fatigue (531; 37%), and shortness of breath (520; 37%). Eighty three subjects (6%) were smokers and 71 (6%), health care providers. Four subjects were exposed in the Hunan Wholesale Seafood Market and 94 (6%), close contact with persons with SARS-CoV-2-infection. Twenty nine subjects (2%) had mild COVID-19, 956 (66%), moderate, 347 (24%), severe and 117 (8%), critical. Lung computed tomography (CT) scan showed bilateral pneumonia in 1215 (87%), groundglass opacity in 1041 (75%), patchy shadows in 579 (42%), and consolidation in 242 (18%). Eight hundred and twentysix (57%) subjects had ≥1 abnormal liver function tests. One hundred and forty-four (10%), acute respiratory distress syndrome (ARDS) and 392 (27%), bacterial co-infections. Other complications had <10% frequencies including heart, acute kidney abnormalities, septic shock, and multiple organ failure. One hundred and fifty-six subjects (14%) received high-flow nasal cannula oxygen, 98 (7%), noninvasive ventilation (no intubation), 54 (4%), invasive ventilation (intubation), and four extracorporeal membrane oxygenation (ECMO). Median ICU stay was 12 days (IQR, 5-21 days). Median intervals from symptom onset to a negative SARS-CoV-2 qRT-PCR RNA, progression and death or discharge were 22 days (IQR 17-28 days), 10 days (IQR 7-14 days), and 30 days (IQR 23-37 days).

At the time of data lock 1327 (92%) subjects were alive and discharged; 122 (8%), died (Table 1) . Subjects who died were significantly older than survivors (median 69 versus 55 years; P < 0.001) and more likely male (74% versus 48%; P < 0.001), with more frequent fatigue (54% versus 35%; P < 0.001), chills (26% versus 15%; P < 0.001), productive cough (50% versus 37%, P = 0.006), shortness of breath (66% versus 35%; P < 0.001), a higher temperature on admission 

We first compared admission hematological co-variates between survivors and non-survivors. Subjects who died had a higher (Table 2) .

We next analyzed baseline blood lymphocyte subsets between subjects who died and survivors (Table 3) Table 4 ). compared with survivors (Table 5 ). Subjects who died were more likely to have abnormal heart, liver, and/or kidney function and to have higher admission median concentrations of interleukin-6 (IL-6; 71 pg/ml [IQR 29-442 pg/ml] versus 9 pg/ml [IQR 4-30 pg/ml]; P < 0.001) and interleukin-10 (IL-10; 11 pg/ml IQR [6-30 pg/ml] versus 4 pg/ml [IQR 3-5 pg/ml]; P < 0.001). There were no significant differences in concentrations of interleukins-2 (IL-2) or -4 (IL-4), tumor necrosis factor (TNF)-α, or interferon (IFN)-γ between survivors and non-survivors.

Next, we studied dynamic changes in hematological covariates between survivors and non-survivors in 390 subjects from Wuhan Third Hospital with daily determinations (Supplementary Table 1 ). Subjects who died had higher concentrations of WBCs, neutrophils, D-dimmer, PT, LDH, and CRP but lower concentrations of lymphocytes and platelets throughout their hospitalization. These dynamic changes are displayed in Fig. 1 .

We analyzed admission hematological co-variates and their multiple measurements considering changes (Δ = Max − Min, Max − baseline, or baseline − Min) correlated with risk of death in all subjects (Supplementary Table 2 NK cell natural killer cell (Table 6 ).

Our data indicate two baseline co-variates (age and Ddimer) on admission and four dynamic co-variates (Δs of concentrations of CRP, LDH, fibrinogen, and platelets) correlate with an increased risk of death in almost 1500 hospitalized persons with COVID-19. In our dataset, we could not confirm other co-variates such as male sex [19] , and comorbidities of atherosclerotic cardiovascular disease [20] and hypertension [21] that had been excluded from the present study. Two admission co-variates correlated with risk of death: age and D-dimer concentration. Similar correlates are reported by others in COVID-19 [8, 19, 20, [22] [23] [24] and in two other coronavirus infections, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome [25, 26] . Age related immune deficiency may be the explanation of this association but is unproved [27] . High D-dimer concentration may result from the inflammation associated with COVID-19 and subsequent activation of coagulation [28] . Several potential risk factors during hospitalization, including disseminated intravascular coagulation, infection, dehydration, prolonged immobilization, mechanical ventilation, and central venous catheter use may further increase D-dimer concentrations [29, 30] .

Four dynamic co-variates correlated with an increased risk of death including Δs of concentrations of CRP, LDH, fibrinogen, and platelets. Similar data are rarely reported in COVID-19-infection [7, 8, 31] . Higher admission LDH concentration was reported to be a risk factor for death by different studies [19, 23, 32] . However, we found the dynamics were more predictive. Han et al. report a dynamic decrease of CRP concentration in 17 subjects with COVID-19 who recovered [31] . There are few data on dynamics of fibrinogen concentration in persons with COVID-19. Tang et al. reported differences in dynamic fibrinogen between survivor and non-survivors, but this dynamic co-variate was not identified to be a risk factor for death [7] . Admission and dynamic platelets are not reported to correlate with risk of death in persons with COVID-19 [22, 33, 34] .

Our study has important limitations. It was retrospective and researchers were not blinded to the outcome when they analyzed the data. Also, we have no external validation cohort. Finally, we did not adjust for multiple comparisons. As such, our conclusions should be interpreted as exploratory and descriptive. Because subjects more likely to die have profound changes in several of these co-variates the correlations we report should not be assumed to be causeand-effect. Fig. 1 Dynamic changes of hematological variables in patients with COVID-19 during hospitalization. The Y-axis "value" include units of all above data: ×10E + 9/L for white bloods cells, neutrophils, lymphocytes, monocytes, and platelets; g/L for hemoglobin, fibrinogen (FIB); mg/L for D-dimer; s for prothrombin time (PT), activated partial thromboplastin time (APTT); U/L for lactate dehydrogenase (LDH); ng/ml for procalcitonin (PCT); mg/L for C-reactive protein (CRP). Data are presented as medians (interquartile ranges, IQR).

In conclusion, we show admission hematological covariates except D-dimer concentration are not associated with an increased risk of death in a large cohort of subjects with COVID-19. However, dynamic measurements of platelets, fibrinogen, CRP, and LDH correlate with risk of death. We await validation of our conclusions.

All data generated or analyzed during this study are included in this published article and its Supplementary Information files. 

Max 1063 14

Total bilirubin, μmol/L (5.1-19) 1245 14

/ml (<100)

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical characteristics of coronavirus disease 2019 in China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine

COVID-19 in persons with haematological cancers

COVID-19 in persons with chronic myeloid leukaemia

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

National Health Commission of China. The novel coronavirus pneumonia diagnosis and treatment program, 7th version

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Perspective: SARS-CoV-2, COVID-19 and haematologists

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Comorbidity and its impact on 1590 patients with Covid-19 in China: a Nationwide analysis

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 From a nationwide analysis in China

Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong

Predictors of mortality in Middle East respiratory syndrome (MERS)

The immunopathogenesis of sepsis in elderly patients

COVID-19 and its implications for thrombosis and anticoagulation

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Hematological findings and complications of COVID-19

Novel coronavirus pneumonia (COVID-19) progression course in 17 discharged patients: comparison of clinical and thin-section CT features during recovery

Development and external validation of a prognostic multivariable model on admission for hospitalized patients with

Association between hypoxemia and mortality in patients with COVID-19

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Author contributions QL, ZC, and YH designed the study. QL, YC, LeC, DW, JY, HW, WH, LC, FD, WeiC, WenC, LL, QR, QL, WR, and FG collected the data. All authors had full access to the data, were involved in data interpretation, and vouch for the accuracy of the analyses. QL, YC, LeC, DW, and RPG prepared the typescript which all authors approved final approval and supported the decision to submit for publication.

Conflict of interest The authors declare that they have no conflict of interest.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.